These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors. Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108 [TBL] [Abstract][Full Text] [Related]
24. May High Levels of Systemic Immune-Inflammation Index and Hematologic Inflammation Markers Suggest a Further Stage in Testicular Tumours? Imamoglu GI; Eren T; Baylan B; Karacın C Urol Int; 2019; 103(3):303-310. PubMed ID: 31466076 [TBL] [Abstract][Full Text] [Related]
25. New emerging targets in cancer immunotherapy: the role of VISTA. Tagliamento M; Bironzo P; Novello S ESMO Open; 2020 Jun; 4(Suppl 3):e000683. PubMed ID: 32554470 [TBL] [Abstract][Full Text] [Related]
26. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695 [TBL] [Abstract][Full Text] [Related]
27. Nature and Significance of Stromal Differentiation, PD-L1, and VISTA in GIST. Hacking S; Wu D; Lee L; Vitkovski T; Nasim M Pathol Res Pract; 2022 Jan; 229():153703. PubMed ID: 34929600 [TBL] [Abstract][Full Text] [Related]
28. VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy? Albertsmeier M; Altendorf-Hofmann A; Lindner LH; Issels RD; Kampmann E; Dürr HR; Angele MK; Klauschen F; Werner J; Jungbluth AA; Knösel T Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205752 [TBL] [Abstract][Full Text] [Related]
29. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390 [TBL] [Abstract][Full Text] [Related]
30. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Kok VC Front Oncol; 2020; 10():268. PubMed ID: 32185135 [TBL] [Abstract][Full Text] [Related]
31. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779 [TBL] [Abstract][Full Text] [Related]
32. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641 [TBL] [Abstract][Full Text] [Related]
33. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476 [TBL] [Abstract][Full Text] [Related]
34. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723 [No Abstract] [Full Text] [Related]
35. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. Zheng SH; Huang JL; Chen M; Wang BL; Ou QS; Huang SY J Neurosurg; 2018 Sep; 129(3):583-592. PubMed ID: 29099300 [TBL] [Abstract][Full Text] [Related]
36. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116 [TBL] [Abstract][Full Text] [Related]
37. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer. Cao X; Ren X; Zhou Y; Mao F; Lin Y; Wu H; Sun Q Front Oncol; 2020; 10():583966. PubMed ID: 33505908 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448 [TBL] [Abstract][Full Text] [Related]
39. Discovery of Benzo[ Wang K; Cai S; Cheng Y; Qi Z; Ni X; Zhang K; Xiao Y; Zhang X; Wang T J Med Chem; 2024 Oct; 67(20):18526-18548. PubMed ID: 39389791 [TBL] [Abstract][Full Text] [Related]
40. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]